BerGenBio 将来の成長

Future 基準チェック /26

BerGenBioの収益は年間23.6%で減少すると予測されていますが、年間収益は年間86.2%で増加すると予想されています。EPS は年間8.8%で減少すると予想されています。

主要情報

-23.6%

収益成長率

-8.8%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	86.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:7BG0 - アナリストの将来予測と過去の財務データ ( )NOK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-287	N/A	N/A	1
12/31/2025	N/A	-194	-223	-220	2
12/31/2024	0	-156	-162	-159	1
9/30/2024	1	-152	-139	-139	N/A
6/30/2024	1	-155	-176	-176	N/A
3/31/2024	1	-155	-192	-192	N/A
12/31/2023	0	-190	-225	-225	N/A
9/30/2023	0	-226	-281	-281	N/A
6/30/2023	0	-258	-282	-282	N/A
3/31/2023	0	-293	-289	-289	N/A
12/31/2022	0	-302	-288	-288	N/A
9/30/2022	1	-294	-290	-290	N/A
6/30/2022	1	-304	-294	-294	N/A
3/31/2022	1	-309	-307	-307	N/A
12/31/2021	1	-309	-303	-303	N/A
9/30/2021	1	-314	-280	-280	N/A
6/30/2021	1	-311	-280	-280	N/A
3/31/2021	1	-290	-246	-246	N/A
12/31/2020	1	-257	-234	-234	N/A
9/30/2020	0	-241	-216	-216	N/A
6/30/2020	0	-218	-187	-187	N/A
3/31/2020	0	-204	-190	-190	N/A
12/31/2019	9	-199	-187	-187	N/A
9/30/2019	11	-193	-186	-186	N/A
6/30/2019	11	-186	-189	-189	N/A
3/31/2019	11	-182	-201	-201	N/A
12/31/2018	2	-192	-187	-187	N/A
9/30/2018	N/A	-188	-180	-179	N/A
6/30/2018	N/A	-186	N/A	-178	N/A
3/31/2018	N/A	-171	N/A	-143	N/A
12/31/2017	N/A	-182	N/A	-168	N/A
9/30/2017	N/A	-162	N/A	-164	N/A
6/30/2017	N/A	-142	N/A	-140	N/A
3/31/2017	N/A	-175	N/A	-173	N/A
12/31/2016	N/A	-130	N/A	-124	N/A
9/30/2016	N/A	-127	N/A	-121	N/A
6/30/2016	N/A	-128	N/A	-119	N/A
3/31/2016	N/A	-82	N/A	-71	N/A
12/31/2015	N/A	-72	N/A	-63	N/A
9/30/2015	N/A	-70	N/A	-61	N/A
6/30/2015	0	-64	N/A	-59	N/A
3/31/2015	1	-57	N/A	-56	N/A
12/31/2014	1	-58	N/A	-54	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 7BG0今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 7BG0今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 7BG0今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 7BG0の収益 ( 86.2% ) German市場 ( 5.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: 7BG0の収益 ( 86.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 7BG0の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

BerGenBio 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

BerGenBio ASA Appoints Olav Hellebø as CEO, Effective November 21, 2024

Martin Olin to Step Down from BerGenBio ASA as CEO

BerGenBio ASA Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

New major risk - Share price stability

New major risk - Market cap size

New major risk - Financial position

BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients

BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.

New major risk - Financial position

BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025

BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer

New major risk - Shareholder dilution

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023

High number of new and inexperienced directors

BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

BerGenBio ASA Announces Board Appointments

BerGenBio ASA to Report Q3, 2023 Results on Nov 14, 2023

BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients

BerGenBio ASA Provides Update on Clinical Development

BerGenBio ASA Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Patients - Primary Efficacy Endpoint Met

Bergenbio Presents Bemcentinib Covid-19 Clinical Trial Data At Eccmid 2022

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

High number of new and inexperienced directors

BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003)

Chief Executive Officer Richard Godfrey has left the company

BerGenBio ASA Presents Encouraging Combined Data for Bemcentinib from Two Phase II Covid-19 Studies At Eccmid

BerGenBio ASA Updates Preliminary Survival Data from the Ongoing Phase II Study of Bemcentinib

BerGenBio ASA Receives Food and Drug Administration Fast Track Designation for Bemcentinib / Anti-Pd-(L)1 Combination in NSCLC

BerGenBio ASAPresents Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC

BerGenBio ASA to Present Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC at ASCO Meeting

BerGenBio ASA Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised Covid-19 Patients

BerGenBio ASA Announces Pre-Clinical COVID-19 Data Presented at Virtual Immunology 2021

BerGenBio ASA Completes Enrolment into Latest Cohort of Phase II Bemcentinib Combination Study in Refractory NSCLC

New 90-day low: €2.90

BerGenBio ASA Announces Start of Phase 1B Trial of Anti-AXL Antibody Tilvestamab (BGB149)

BerGenBio ASA Closes Recruitment into Trial Assessing Bemcentinib in Covid-19 Patients

Revenue in line with expectations

BerGenBio ASA Announces Second Data Monitoring Committee Recommends Continuation of Bergenbio's BGBC020 Trial Assessing Bemcentinib in COVID-19 Patients

BerGenBio ASA Presents an Update from Its Phase II Study of Bemcentinib in Combination with Anti-PD-1 Therapy Pembrolizumab (Bgbc008)

Bergenbio to Present Updates from Ongoing Phase II Bemcentinib Combination Study in Refractory NSCLC At WCLC 2020

New 90-day high: €3.47

BerGenBio ASA to Report Q4, 2020 Results on Feb 10, 2021

BerGenBio ASA to Report Q3, 2021 Results on Nov 16, 2021

New 90-day high: €3.31

BerGenBio ASA Presents Updated Clinical Data from Two Phase II Studies of Bemcentinib in AML and MDS Patients at ASH 2020

BerGenBio ASA Confirms First Patient Enrolled in Phase II Trial Assessing Bemcentinib as Potential Treatment for COVID-19 in India

Revenue in line with expectations

BerGenBio ASA Presents Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting

New 90-day low: €2.52

BerGenBio ASA to Present Clinical Translational Data from the Ongoing Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting

BerGenBio Presents Data on Anti-Axl Antibody Tilvestamab

BerGenBio Announces First Patient Dosed with Bemcentinib in Relapsed Malignant Pleural Mesothelioma Investigator Sponsored Phase IIa Study

Bergenbio ASA Receives Regulatory Approval from the India Regulatory Authority to Proceed with Phase II Clinical Trial to Assess the Efficacy and Safety of Bemcentinib

BerGenBio ASA Receives Approval from Norwegian Regional Ethics Committee for COVID-19 South Africa Trial

New 90-day low: €2.67

BerGenBio ASA to Report Q2, 2020 Results on Aug 18, 2020

First half earnings released

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘